Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report published on Monday morning. The firm issued a sell rating on the stock.

Moleculin Biotech Trading Down 3.0 %

Shares of MBRX stock opened at $0.39 on Monday. Moleculin Biotech has a 1 year low of $0.34 and a 1 year high of $1.65. The firm’s fifty day moving average price is $0.58 and its two-hundred day moving average price is $0.70. The firm has a market capitalization of $11.48 million, a P/E ratio of -0.38 and a beta of 1.97.

Moleculin Biotech (NASDAQ:MBRX) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.08. During the same quarter last year, the business earned ($0.24) earnings per share. As a group, equities research analysts forecast that Moleculin Biotech will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Moleculin Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in shares of Moleculin Biotech by 79.3% in the 1st quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock valued at $107,000 after acquiring an additional 26,500 shares during the period. State Street Corp grew its position in shares of Moleculin Biotech by 19.2% in the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after acquiring an additional 11,497 shares during the period. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Moleculin Biotech in the 4th quarter valued at about $39,000. 7.67% of the stock is currently owned by institutional investors and hedge funds.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.